Mark Agulnik is an Oncology physician. OpenAlex indexes 259 publications with 10,360 citations (h-index 46); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1441 Eastlake Ave
Los Angeles, CA 900893012
Telephone
323-865-3000Provider last certified this registry record 8 May 2024.
Clinical trials
- Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Sponsor: Northwestern University
- Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Sponsor: Northwestern University
- A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
Sponsor: Northwestern University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Deciphera Pharmaceuticals Inc.Program year202529 payments$27,155openpaymentsdata.cms.gov ↗
- Daiichi Sankyo Inc.Program year20252 payments
- SpringWorks Therapeutics, Inc.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2022 - Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma
Nature Communications
2022 - NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022
Journal of the National Comprehensive Cancer Network
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”